Dawn Surprenant
Family · Hartford, CTNPI 1497406235
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Abbott at 54.0% of the total. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $63.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$2K
- Edwards Lifesciences$578
- Actelion Pharmaceuticals US, Inc.$254
- AstraZeneca$214
- Novartis$174
- plus $700 from 9 others
What the payments were for
- Consulting fees$1,25214%
- Travel & lodging$2,98234%
- Food & beverage$4,40850%
- Education$1892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 69 | $4,769 |
| Medtronic | 19 | $2,142 |
| Edwards Lifesciences | 2 | $578 |
| Actelion Pharmaceuticals US, Inc. | 7 | $254 |
| AstraZeneca | 5 | $214 |
| Novartis | 7 | $174 |
| Boehringer Ingelheim | 7 | $139 |
| Alnylam Pharmaceuticals Inc. | 4 | $117 |
| Boston Scientific | 1 | $116 |
| Pfizer | 4 | $91 |
| Impulse Dynamics (USA) Inc. | 8 | $86 |
| Merck | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Bridgebio Pharma, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,982
- HeartMate Touch$1,071
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$736
- COREVALVE EVOLUT R$135
- WAINUA$125
- WATCHMAN FLX$116
- SAPIEN 3 Ultra RESILIA$111
How this compares
$8,832 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $82,885 |
| EntrestoSacubitril/Valsartan | 65 | $79,685 |
| EliquisApixaban | 31 | $40,933 |
| FarxigaDapagliflozin Propanediol | 24 | $28,441 |
| Torsemide | 186 | $8,020 |
| Potassium Chloride | 57 | $3,040 |
| Eplerenone | 29 | $2,738 |
| Bumetanide | 23 | $830 |
| Spironolactone | 115 | $659 |
| Warfarin Sodium | 78 | $625 |
| Metoprolol Succinate | 70 | $532 |
| Klor-Con M20Potassium Chloride | 12 | $338 |
| Minocycline Hcl | 16 | $337 |
| Metolazone | 21 | $306 |
| Pantoprazole Sodium | 28 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $139 | $82,88573 claims |
| NovartisEntresto | $174 | $79,68565 claims |
| PfizerEliquis | $91 | $40,93331 claims |
| AstraZenecaFarxiga | $214 | $28,44124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Hartford
- Katherine StockeyHartford$10K
- Cangwa LinHartford$9K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.